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. Introduction
The 30th meeting of the European Lipoprotein Club was
eld from 3 to 6 September at the Evangelische Akademie
n Tutzing Germany and attended by some 120 participants
rom all over Europe and the United States. On Monday night,
fter the welcome by the ELC secretary, Marten Hofker,
wo state of the art lectures were presented by, respectively,
laus Lindtpaintner (Basel, Switzerland) and Go¨ran Hans-
on (Stockholm, Sweden). Klaus Lindtpaintner spoke on
Biomarkers and personalized medicine: hype, hope and
mportance of being earnest”. Go¨ran Hansson’s presenta-
ion was entitled: “Grease or heat? Liposuction or Aspirin?
houghts on the Pathology and Treatment of Atherosclero-
is”.
On Tuesday, the first session focused on vascular biol-
gy and atheroslerosis and was introduced by Ira Tabas
New York, USA). His presentation was entitled: “From
therosclerosis to innate immunity; lessons from study-
ng how macrophages die”. The second session revolved
round lipid transport and was introduced by Daniel Rader
Philadelphia, USA), with a presentation entitled: “Molecular
egulation of reverse cholesterol transport”. On Wednesday,
he third session focused on diagnostic and therapeutic tar-
ets. Lawrence Chan (Houston, USA) presented an invited
ecture on the advances in gene therapy for familial hyper-
holesterolemia and diabetes. The fourth session on gene
egulation was introduced by Richard Deckelbaum (New
ork, USA) and he presented a lecture entitled: “Post-
ranscriptional regulation of SREBP by three interdependent
ut distinct mechanisms”. The fifth session on metabolic syn-
rome was introduced by Mark McCarthy (Oxford, UK) on
enetic and genomic biomarkers for type 2 diabetes. The
nal “Varia” session on Thursday, consisted exclusively of
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oi:10.1016/j.atherosclerosis.2007.12.022To promote participation by junior researchers, two types
f awards were presented to two young scientists. The young
nvestigator award was presented to Oliver Bruns (Hamburg,
ermany) for his presentation entitled: “Non-invasive in vivo
maging of recombinant TRL labeled with nanocrystals”. The
oster award was presented to Philip Gordts (Leuven, Bel-
ium) for his poster entitled: “Inactivation of the NPXYXXL
omain and downstream motifs of LRP1 show a differential
ncrease in atherosclerosis”. The winner of the poster prize
as also given the opportunity to orally present his poster in
he “Varia” session.
. State of the art lecture
Chaired by Marten Hofker (Groningen, The Netherlands).
The scientific part of this year’s meeting was opened by
wo state of the art lectures that provided future perspec-
ives from both industry and academia. Klaus Lindtpaintner
Roche, Basel) opened with his presentation that was ade-
uately entitled “Biomarkers and Personalized Medicine:
ype, Hope and Importance of Being Earnest”. He shared
is view of the hypes around personalized medicine, where
verybody is expecting a sudden revolution based on the
ovel technologies in biomedical research. He pointed out,
owever, that in the field of cardiovascular diseases it is
lready customary to carry out careful diagnosis and ther-
py based on biomarkers. In particular, measurements of
ipoproteins and the interpretation of the lipoprotein profiles
re being done with high accuracy. There are excellent algo-
ithms, such as Procam, to further aid the interpretation of theiomarkers that would markedly improve our ability to pre-
ict disease susceptibility or to guide treatment. Although
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ne of the best examples of success of genetic stratification
f patients to select responders to a particular treatment is
he use of the anticancer drug Iressa in certain forms of small
ell lung cancer. This treatment is very effective in carriers
f a susceptible Epidermal Growth Factor Receptor (EGFR)
llele. Unfortunately, examples such as this are rare. One
hould not expect genomic approaches to easily lead to the
iscovery of genetic variants or biomarkers showing similar
iscriminatory power. Dr. Lindpaintner was earnest in stating
hat genetics and other sources of potential new biomark-
rs simply did not deliver the tools for improving prediction
et, and also the effect sizes observed with genetic risk alle-
es prohibit current application in diagnosis. Nevertheless, he
emained optimistic that the current research would gradually
mprove this situation and that serendipitous findings may
ccur, reminiscent of Iressa, so that the goal of personalized
edicine becomes reality.
The lecture from Go¨ran Hanson (Stockholm, Sweden)
as entitled: “Grease or heat? Liposuction or Aspirin?
houghts on the Pathology and Treatment of Atheroscle-
osis”. He pointed out that much of the insight into the
echanisms of atherosclerosis has been driven by research
n the area of lipid metabolism and that lipid lowering has
een and still is very important in the battle against car-
iovascular diseases. However, he also explained that lipid
owering only has modest effects on the hard end points, such
s CVD death. When studying the pathogenesis of atheroscle-
osis, it becomes clear that inflammation plays a crucial role.
ence, for defining novel therapeutic targets, it is very impor-
ant to understand the role of the immune system in athero-
clerosis.
A significant amount of immune reactivity can be observed
n the plaque as evidenced by the presence of macrophages
nd T-cells, MHC molecules, and inflammatory mediators
uch as cytokines. Moreover, LDL, one of the major athero-
enic lipoproteins, can undergo immunogenic modifications
nd yield phospholipid fragments (e.g. phosphorylcholine
nd PAPC) and modified APOB, which in turn can be rec-
gnized by the immune system. One of the major goals is
o identify the “bottleneck” factors that drive atherogenesis.
ne of these potential bottlenecks could be the tumor necro-
is factor (TNF) gene family. Interestingly, TNF is linked to
etabolic processes and is well known to inhibit lipopro-
ein lipase (LPL). Recently, however, the role of another
NF gene family member, LIGHT, has attracted consider-
ble attention. This gene is mainly expressed in T-cells and
endritic cells. Remarkably, overexpression of LIGHT on
-cells in mice leads to hyperlipidemia. This effect could
e reversed when blocking the lymphotoxin-beta receptor,
he main receptor for LIGHT. Interestingly, also other mem-
ers of the TNF family, such as OX40L and CD137 play an
mportant role in T-cells and have marked effects on atheroge-
esis. These studies have disclosed an important relationship
etween T-cell genes, metabolism and cardiovascular disease
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. Session I
Vascular biology and atherosclerosis: chaired by Ko
illems van Dijk (Leiden, The Netherlands) and Ken Lind-
tedt (Helsinki, Finland).
The vascular biology and atherosclerosis session was
pened by Ira Tabas (New York, USA) on the lessons learnt
rom dying macrophages in atherosclerosis and innate immu-
ity. The formation of a necrotic core, consisting of dead and
ying macrophages in an atherosclerotic lesion constitutes
he main risk factor for lesion rupture. Such a lesion has also
een termed the vulnerable plaque. Ira Tabas started off by
arning the audience about the complexity of the processes
hat are involved in the formation of the necrotic core. Many
its are required for the induction of macrophage apoptosis
nd any single hit is not sufficient as one would expect for
uch a potentially dangerous process. He identified at least
our different players in macrophage apoptosis: (1) endoplas-
ic reticulum (ER) stress via the unfolded protein response
UPR), which is induced, for example, by oxidized phospho-
ipids; (2) the scavenger receptor A (SRA), which is activated
y modified lipoproteins; (3) the toll like receptor 4, which is
ctivated by SRA ligands, saturated fatty acids, and other sub-
tances in lesions; and (4) a rise in cytosolic calcium levels.
Both the SRA and TLR4 are pattern recognition receptors.
ctivation of TLR4 results in the induction of both a cell
urvival pathway via the TRIF-TRAM-IRF-3-IFNb branch
f TLR4 signaling and apoptosis via the Myd88-Mal branch.
n the presence of “classic” TLR4 activation, such as via
PS, the cell survival pathway is dominant over the apoptosis
athway. However, in the presence of SRA ligands, such as
odified lipoproteins that are present in the lesion, the cell
urvival pathway is selectively shut down and the cell will go
nto apoptosis—all in the setting of ER stress.
The interaction between pattern recognition recep-
ors such as the SRA and TLR4 (and other previously
escribed combinations) could be a means to provide an
nnate host defense against organisms that hide inside liv-
ng macrophages. Intriguingly, this evolutionary conserved
echanism wreaks havoc in the atherosclerotic plaque and
enders it vulnerable to rupture.
Ernst Malle (Graz, Austria) showed that the soluble
art of the receptor for advanced glycation end products
sRAGE) binds with high affinity to hypochlorous acid-
odified LDL (HOCl-LDL), and thereby effectively inhibits
ptake and accumulation of HOCl-LDL by macrophages.
RAGE also form a co-precipitable complex with HOCl-
DL in serum. sRAGE was found to specifically inhibit the
nteraction between HOCl-LDL and the scavenger recep-
or CD36. Finally, Malle proposed that sRAGE, by being
physiological antagonist for CD36-mediated accumulation
f cholesterol in phagocytes, may act as a sink for HOCl-LDL
n atherosclerotic lesions.
The study by Cinzia Parolini (Milan, Italy) evaluated, in
ivo, the minimal dose of apoA-IMilano phospholipid com-






































































































tMeeting report / Athero
rabbit model of lipid-rich plaques. Thirty-six rabbits under-
ent perivascular injury at both carotids, followed by a 1.5%
holesterol diet. After 90 days, rabbits were randomly divided
nto six groups and treated five times with vehicle or differ-
nt doses of ETC-216, once every four days. Carotid plaque
hanges were evaluated in vivo by IVUS and MRI. The
inimal effective dose needed for regression of atheroscle-
osis (−1.56%) was found to be 20 mg/kg and the best result
−6.83%) was obtained with the maximal dose of ETC-216
sed. A significant regression was achieved with only two
dministrations of the highest dose. The author concluded
hat repeated infusions of low doses of ETC-216 effectively
ffected atherosclerosis in an animal model.
Ko Willems van Dijk (Leiden, The Netherlands) pre-
ented data on a role for maternal genotype and associated
ypercholesterolemia on the developing vascular systems
n heterozygous apoE-deficient mice. Carotid artery plaque
ormation was induced in adult mice by a constrictive perivas-
ular collar placement. The authors found that maternal
poE-deficiency affected the carotid endothelial function in
etuses, but found no signs of fatty streak formation in pre-
r postnatal animals. However, collar-induced carotid lesion
evelopment was highly increased in adult offspring of mater-
al apoE-deficiency compared to offspring of maternal wild
ype. The author concluded that maternal apoE-deficiency
ot only affects the endothelium of fetal arteries but also
ncreases the susceptibility for development of collar-induced
therosclerosis in adult life, by epigenetic mechanisms.
. Session II
Lipid transport: chaired by Franco Bernini (Parma, Italy)
nd Joerg Heeren (Hamburg, Germany).
The lipid transport session was opened with an invited
ecture given by Daniel Rader (Philadelphia, USA) on
he molecular regulation of reverse cholesterol transport
RCT) in vivo. He first reported results obtained modulating
he host mice specifically using a vector based on adeno-
ssociated virus serotype 8 (AAV8) to evaluate the effect of
ETP expression in mice (which naturally lack CETP) on
acrophage RCT. The experiment included mice that lacked
he low-density lipoprotein receptor or the scavenger receptor
lass B, type I (SR-BI). He demonstrated that CETP expres-
ion promotes macrophage RCT in mice, that this effect is
ependent on the low-density lipoprotein receptor, and that
ETP expression restores to normal the impaired RCT in
ice deficient in SR-BI. Based on these findings he raised
he possibility that the CETP inhibitors may have beneficial
ffects for some people and not for other based on the expres-
ion of LDL receptors. Dr. Rader also investigated the still
nknown contributions of macrophage ATP-binding cassette
ransporter A1 (ABCA1), SR-BI, and ABCG1 in mediating
CT from macrophages in vivo. To achieve this aim, pharma-
ological means, such as LXR agonists, were used combined
ith the injection in host mice of genetically manipulated
b
s
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rimary macrophages. He reported that macrophages lacking
BCA1 had a significant reduction in macrophage RCT in
ivo, demonstrating the importance of ABCA1 in promoting
acrophage RCT, however, substantial residual RCT existed
n the absence of macrophage ABCA1. Using macrophages
eficient in SR-BI expression, he showed that macrophage
R-BI does not contribute to macrophage RCT in vivo. To
nvestigate whether ABCG1 was involved in macrophage
CT, he used ABCG1-overexpressing, -knockdown, and -
nockout macrophages showing that increased macrophage
BCG1 expression significantly promoted while knockdown
r knockout of macrophage ABCG1 expression significantly
educed macrophage RCT in vivo. The additive effect of
oth ABCA1 and ABCG1 in promoting macrophage RCT
n vivo was also demonstrated. The risk of atherosclerosis
s inversely associated with plasma levels of high-density
ipoprotein cholesterol (HDL-C). However, Dr. Rader under-
ined that HDL metabolism is incompletely understood, and
here are few effective approaches to modulate HDL-C levels.
e reported that inhibition in the liver of the classical pro-
rotein convertases (PCs), decreases plasma HDL-C levels.
his metabolic effect of hepatic PCs is critically depen-
ent on expression of endothelial lipase (EL), an enzyme
hat directly hydrolyzes HDL phospholipids and promotes
ts catabolism. Hepatic PCs reduce EL function through
irect inactivating cleavage of EL as well as through acti-
ating cleavage of angiopoietin-like protein 3 (ANGPTL3),
n endogenous inhibitor of EL. Inhibition of hepatic PCs
esults in increased EL activity and reduced HDL-C as well as
mpaired RCT in vivo. Therefore, the hepatic PC-ANGPTL3-
L-HDL pathway could be a novel mechanism controlling
DL metabolism and cholesterol homeostasis.
CarlosVrins (Amsterdam, The Netherlands) discussed the
ffect of PPAR-delta activation on the intestinal cholesterol
fflux pathway. Previous studies have shown that activation
f PPAR-delta is associated with an increase of fecal sterol
ecretion, which could only partially be explained by reduced
holesterol absorption. This study was aimed to investigate
hether this activation not only affects intestinal absorption
ut also secretion. The author reported that treatment of FVB
ild type mice with the PPAR-delta agonist GW610742X did
nduce the intestinal cholesterol efflux without affecting total
erum cholesterol and the hepatobiliary cholesterol secretion.
he reduction in intestinal NPC1L1 gene expression indi-
ated the expected change in intestinal cholesterol absorption
s reported earlier. Possible involvement of NPC1L1 in
ntestinal cholesterol efflux was tested with the inhibitor eze-
imibe. Feeding mice with ezetimibe did not affect intestinal
holesterol secretion. Based on these results, it was concluded
hat the previously observed increase in neutral sterol secre-
ion upon PPAR-delta activation can be explained in part by
he increased direct intestinal cholesterol secretion.Zhao-Yan Jiang (Stockolm, Sweden) discussed the possi-
le contribution of several hepatic genes to biliary cholesterol
uper-saturation, a prerequisite for cholesterol gallstone for-
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f gallstone patients (GS) and gallstone free patients (GSF),
t was found that in GS, gallbladder bile was more satu-
ated with cholesterol than in GSF, due to increased molar
of cholesterol. The expression of ABCG5, ABCG8, and
f LXR-alpha was increased in GS patients. In addition,
he mRNA and protein of SR-BI were also increased in
S patients as compared to GSF subjects. The increased
xpression of the canalicular cholesterol transporters ABCG5
nd ABCG8 may account for super-saturation of the bile
ith cholesterol in GS patients and the excessive biliary
holesterol may originate from the uptake of plasma HDL
holesterol via increased expression of SR-BI.
Ryan E. Temel (Winston-Salem, USA), reported on the
ole of hepatic Niemann-Pick C1-Like 1 (NPC1L1) in biliary
holesterol concentration. Humans highly express NPC1L1
n the liver but the exact function of hepatic NPC1L1 is
nknown. They recently described that human NPC1L1
xpression in hepatoma cells facilitates free cholesterol
ptake from the culture medium. Creating transgenic mice
verexpressing NPC1L1 they tested the hypothesis that hep-
tic NPC1L1 allows the retention of biliary cholesterol by
epatocytes and that ezetimibe disrupts the hepatic function
f NPC1L1. The overexpression of NPC1L1 resulted in a
0- to 20-fold decrease in biliary cholesterol concentration
ssociated with a 30%–60% increase in plasma cholesterol.
iliary and plasma cholesterol levels were almost normalized
ith ezetimibe treatment suggesting that in humans, ezetim-
be may reduce plasma cholesterol by inhibiting NPC1L1
unctions in both intestine and liver, and that hepatic NPC1L1
ay protect the body from excessive biliary loss of choles-
erol.
The second invited speaker of this session Laurent Lagrost
Dijon, France) described the pleiotropic effects of plasma
hospholipid transfer protein (PLTP). PLTP belongs to
he lipid transfer/lipopolysaccharide binding protein family
hat includes the cholesteryl ester transfer protein (CETP),
he bactericidal permeability increasing protein and the
ipopolysaccharide-binding protein. Dr. Lagrost showed that
LTP can act in several distinct metabolic processes such
s the molecular transfer of phospholipids and alpha toco-
herol but also lipopolysaccharides suggesting that PLTP
ight be involved both in lipoprotein metabolism and in
ntimicrobial defence. The potential role of PLTP in the
evelopment of atherosclerosis has not been fully eluci-
ated. While systemic PLTP activity correlate positively
ith the risk of cardiovascular disease, an atheroprotective
ole of macrophage-derived PLTP was observed in LDL
eceptor deficient and apolipoprotein E deficient mice. In
iabetic patients, who have increased plasma PLTP activity,
he lipoprotein distribution of alpha tocopherol is depen-
ent on PLTP activity. To circumvent the problem that mice
o not express CETP, Dr. Lagrost performed studies with
LTP-transgenic rabbits which are characterized by a more
uman-like lipoprotein metabolism. There was no direct cor-
elation between the concentration of alpha tocopherol and




iis 197 (2008) 471–479
ompared to the control groups PLTP-transgenic rabbits
ave (a) more atherosclerotic lesions, (b) increased levels
f LDL cholesterol and (c) reduced alpha tocopherol lev-
ls demonstrating the important role of PLTP for lipoprotein
etabolism and the development of atherosclerosis.
Lars Bo Nielsen (Copenhagen, Denmark) described in his
resentation the effect of apolipoprotein M (apoM) on HDL
etabolism and atherosclerosis. ApoM is a novel apolipopro-
ein mainly present in high-density lipoprotein (HDL). It
elongs to the lipocalin protein superfamily and is secreted
ithout cleavage of its hydrophobic signal peptide, which
robably anchors apoM in the phospholipid layer of plasma
ipoproteins. Dr. Nielsen showed that the concentration of
DL is increased in mice which express the human apoM-
ransgene, while apoM-deficient mice have decreased HDL
evels. Detailed studies analyzing the lipoprotein composi-
ion did not reveal differences in the size and charge of HDL
etween the different genotypes analyzed. However, the con-
ersion of HDL particles mediated by LCAT-dependent and
ndependent mechanisms were influenced by the presence
f apoM. Moreover, apoM expression protects against the
evelopment of atherosclerosis on the LDL receptor deficient
ackground which might be explained by (a) the modulation
f plasma HDL particles, (b) by apoM-facilitated cholesterol
fflux or (c) by the anti-oxidative effect of apoM.
Stefan K. Nilsson (Umea˚, Sweden) provided new insights
n the triacylglycerol (TG)-lowering effect of apolipopro-
ein A-V (apoAV). ApoAV has been shown to modulate the
ipolytic activity of lipoprotein lipase. However, more than
9% of apoAV is associated with the liver and therefore the
uthor proposed that apoAV might influence the internaliza-
ion of TG-rich lipoproteins by mediating the interaction of
ipoproteins with their respective receptors. By surface plas-
on resonance studies, he showed that both lipid-free and
ipidated apoAV interacts with LRP1 and SorLA, both mem-
ers of the LDL receptor family, as well as with the Sortilin
eceptor of the Sortilin gene family. Furthermore, the bind-
ng of chylomicrons to these receptors was enhanced in the
resence of apoAV. In cellular studies using HEK293 cells
ransfected with SorLA, and with cells transfected with Sor-
ilin, he showed that lipid-associated apoAV is internalized
ia receptor-mediated endocytosis. The author concluded that
poAV exerts its TG-lowering effect by receptor mediated
ipoprotein clearance.
Willeke de Haan (Leiden, The Netherlands) identified the
inimal domain of apolipoprotein CI (apoCI) that specif-
cally inhibits the activity of CETP. ApoCI is present on
G-rich lipoproteins and HDL and has several roles in
ipoprotein metabolism, such as the inhibition of lipoprotein
ipase, inhibition of the apoE-mediated hepatic remnant clear-
nce and inhibition of CETP. To identify a novel HDL-raising
nd therefore potential anti-atherogenic drug, the author cre-
ted different apoC-I peptides and analyzed the potential of
hese molecules to inhibit CETP and LPL activity. Whereas
poC-I N-terminal fragments showed only negligible CETP
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nhibited CETP activity. This CETP inhibitory effect was
ainly dependent on positively charged residues. Since LPL
ctivity was not influenced by the apoCI 32–57 peptide, the
uthor concluded that this fragment might be an interesting
ovel ‘drugable’ CETP inhibitor.
LuciaRohrer (Zurich, Switzerland), investigated how high
ensity lipoprotein HDL and its major protein constituent
polipoprotein apoA-I are transported from the blood stream
nto the vascular wall to exert their anti-atherogenic prop-
rties within the arterial wall. They previously showed that
BCA1 mediates apoA-I transcytosis in endothelial cells.
ere the author specifically looked at the interaction of HDL
ith the endothelial cells. It was found that endothelial cells
ound both I125-apoAI and I125-HDL with high affinity and
n a saturable manner and that binding and cell association
f HDL was only competed by excess of HDL and not by
poA-I or albumin. Through biotinylation experiments, it was
lso demonstrated that endothelial cells internalize labeled
DL and that only a minor amount of the internalized HDL
as degraded. Modulating ABCG1 and SR-BI with RNA
nterference it was demonstrated that HDL transport was
educed indicating that endothelial cells transcytose HDL in
n ABCG1 and/or SR-BI dependent process.
. Session III
Diagnostic and therapeutic targets: chaired by Dilys Free-
an (Glasgow, UK) and Florian Kronenberg (Innsbruck,
ustria).
Lawrence Chan (Houston, Texas, USA) gave an overview
n the use of gene therapy to treat familial hypercholes-
erolaemia (FH) and diabetes. In an LDL receptor knockout
ouse model of FH, gene transfer of the LDL recep-
or resulted in a marked reduction in plasma cholesterol,
ncreased LDL turnover, reduced atherosclerosis and longer
urvival. Similar studies in heterozygous FH rhesus mon-
eys using the LDL receptor gene in an helper-dependent
ector injected into the hepatic artery were somewhat less
uccessful with a requirement for high gene doses and a
hort duration of response. The duration of response was
mproved by using a balloon catheter based delivery sys-
em to occlude hepatic venous drainage. The second topic
ooked at type 1 and 2 diabetes which feature pancreatic
eta cell dysfunction. Gene transfer of pro-insulin or mod-
fied insulin with a glycaemia-regulated promoter has not
orked well in experimental animals since the physiological
egulation of insulin secretion is not replicated. An alterna-
ive approach is to induce beta cell formation in the liver
y the delivery of developmental transcription factors to the
iver. Transfer of PDX-1 into a streptozotocin-induced mouse
odel of diabetes, although increasing plasma insulin and
educing plasma glucose resulted in severe fulminant hepati-
is due to the concomitant induction of exocrine pancreatic
ells. Transfer of a transcription factor further downstream in
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long with the gene for a beta cell stimulating hormone, beta-
ellulin, restored insulin levels and glucose tolerance in the
iabetic mice. Furthermore, plasma insulin levels were down-
egulated in response to fasting. One approach to treating
nsulin resistance is to reverse obesity. Chan and colleagues
ave interrupted the capillary blood supply to adipose tissue
y targeted induction of apoptosis. Blood vessels supplying
articular tissues are unique and express difference surface
olecules. Phage display was used to identify a peptide motif
hat acts as a marker of the vasculature of adipose tissue. A
ro-apoptotic peptide was then targeted to this marker result-
ng in fat ablation. In mice, molecular fat ablation does not
esult in accumulation of fat in other tissues and metabolic
bnormalities were corrected, possibly because molecular
blation targets both subcutaneous and visceral fat. It will be
ascinating to discover whether peptide-mediated fat ablation
ill work in humans.
Patrick Rensen (Leiden, The Netherlands) reported their
nvestigations on the HDL-raising effects of niacin. They used
emale APOE*3-Leiden transgenic mice with the human
ETP transgene under control of its natural flanking regions
nd fed them with a Western-type diet with or without niacin.
iacin dose-dependently decreased plasma total cholesterol
nd triglycerides and increased HDL-C and apoAI. Inter-
stingly, APOE*3-Leiden mice that do not express CETP
howed no HDL-increasing effect of niacin. The authors fur-
her showed that niacin dose-dependently decreased plasma
ETP mass and activity. These experiments clearly demon-
trated that the HDL-increasing effect of niacin is caused by
decreased cholesteryl ester transfer from HDL to (V)LDL.
Ivan Tancevski (Innsbruck, Austria) presented their results
n the novel liver-selective thyromimetic T-0681 which dis-
lays strong hypolipidemic properties without cardiotoxic
ffects. The authors used BALB/c mice and New Zealand
hite rabbits fed a high-cholesterol diet. They showed with
hese two models that T-0681 decreases plasma cholesterol
nd triglycerides levels by a pronounced increase in the hep-
tic expression of scavenger receptor-BI as well as the LDL
eceptor without changes in plasma CETP-activity. Addi-
ionally, T-0681 was shown to promote reverse cholesterol
ransport from macrophages to faeces in vivo. In cholesterol
ed rabbits, treatment with T-0681 led to a 60%-decrease
f atherosclerotic lesion area. These data suggest that liver-
elective thyromimetics may prove useful therapeutic agents
gainst the development of atherosclerosis in humans.
Lena Persson (Huddinge, Sweden) investigated the role of
CSK9 in the hormonal regulation of hepatic LDL receptors
LDLRs). The experiments showed that cholesterol-feeding
educed LDLR mRNA whereas LDLR protein was induced;
oncomitantly PCSK9 mRNA was reduced. Similar effects
ere observed for glucagon. However, estrogen treatment
nduced LDLR mRNA and LDLR protein; concomitantly
CSK9 mRNA was reduced. Other hormones such as thy-
oid hormone, growth hormone, insulin and IGF-1 were also
nvestigated. PCSK9 showed a pronounced and highly sig-
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stablished to modulate hepatic LDL receptor expression.
hese findings suggest that PCSK9 is important in the hor-
onal regulation of hepatic LDLRs.
. Session IV
Gene Regulation: chaired by Gertrud Schuster (Davis,
SA) and Paolo Parini (Stockholm, Sweden).
Richard Deckelbaum (New York, USA) gave an overview
n their recent findings on the “post-transcriptional regulation
f SREBP by three independent but distinct mechanisms”.
terol regulatory element binding protein (SREBP) medi-
tes the functions of fatty acids and cholesterol by binding
o sterol regulatory elements (SRE) present in the promoter
f genes involved in various aspects of lipid and cholesterol
omeostasis such as plasma lipid levels, intracellular lipid
ontent, and membrane physiology. SREBP precursor protein
pSREBP) is embedded in the ER and is known to be activated
y sterol depletion due to proteolysis by interacting with
nother ER membrane protein SREBP cleavage-activating
rotein (SCAP); however, the question of whether the con-
ersion of pSREBP to mature SREBP (mSREBP) is a single
ssential or multiple control pathway still remains.
In previous studies Richard Deckelbaum and colleagues
Tilla S. Worgall and Rebecca Juliano) showed that fatty acids
egulate SRE-mediated gene transcription by decreasing
SREBP in the absence of cholesterol as well as synergis-
ically with cholesterol. In addition, fatty acids can affect
RE-mediated gene transcription by two independent mech-
nisms. (1) Fatty acids can induce sphingomyelin hydrolysis,
hich can result in the intracellular displacement of mem-
rane cholesterol. (2) sphingomyelin hydrolysis also results
n the generation of ceramide, which can decrease levels of
ranscriptionally active mSREBP and SRE-mediated gene
ranscription. In addition, they unraveled with fluorescence
agged proteins that cholesterol, ceramide, and unsaturated
atty acids regulate SREBP processing at different points.
hereas cholesterol inhibits the translocation of SREBP and
CAP into the nucleus and Golgi apparatus, but not general
esicular trafficking, ceramide disrupts all vesicular traffick-
ng of SREBP and SCAP from the ER to the Golgi apparatus.
inoleic acid prevents their migration into the nucleus, from
he ER and Golgi, but does not inhibit SCAP trafficking from
he ER to the Golgi apparatus. In conclusion these data open
he door for the development of new pathways and perhaps
herapeutics agents interfering with the SREBP trafficking
athways and the regulation of genes involved in lipid and
holesterol homeostasis.
Harald Funke (Jena, Germany) reported on the interac-
ions of monocytes and T-lymphocytes with the vessel wall
rom patients with familial hypercholesteremia (FH), leading
o differences in intracellular lipoprotein metabolism. They
ound a considerable amount of genes that are up-regulated
n T-lymphocytes in FH patients, suggesting an acceler-




Iis 197 (2008) 471–479
H monocytes are characterized by increased distribution
f scavenger receptors, like CD36, CD68, and low-density
ipoprotein-related protein 1 (LRP-1) which is associated
ith elevated uptake of native as well as oxidized LDL.
lthough in patients with FH the circulating number of
D14+/CD16+ positive monocytes is decreased, there is an
ncrease of CD29 and CD11c, which are typically expressed
n dendritic cells.
Mohamed Amine Bouhel (Lille, France) presented on
he ability of PPAR-gamma activation to prime human
onocytes into alternative M2 macrophages with anti-
nflammatory properties. Th1 cytokines promote the M1
ro-atherogenic activation, while Th2 cytokines attenuate
acrophage-mediated inflammation leading to an “alter-
ative” M2 macrophage phenotype. In the presence of
L-4, PPAR-gamma has the ability to prime primary human
onocytes toward alternative M2 differentiation. When
PAR-gamma is stimulated, cell culture medium from
2 differentiated macrophages exerts more pronounced
nti-inflammatory properties on M1 macrophages than
he medium from un-stimulated M2 macrophages. PPAR-
amma activation did not affect the expression of M2 markers
n resting and in M1 macrophages, suggesting that only native
onocytes could be primed by PPAR-gamma to an enhanced
2 phenotype. Finally in humans, PPAR-gamma activation
y pioglitazone administration significantly increased the
xpression of the M2 marker CD206 in blood monocytes.
hese data together suggest that PPAR-gamma may exert
nti-inflammatory activities by promoting the differentiation
f human monocytes toward a M2 phenotype.
The session was concluded with a contribution from
uth Frikke-Schmidt (Copenhagen, Denmark) who presented
n the predictive power of a functional promoter variant
n the zinc finger protein 202 for severe atherosclerosis
nd ischemic heart disease (IHD). ZNF202 is a transcrip-
ional repressor controlling promoter elements found in genes
nvolved in vascular maintenance and lipid metabolism. The
ypothesis tested was that a common variant, g.-660A > G, in
NF202 promoter is functional, predicts severe atheroscle-
osis, and predicts ischemic heart disease. In vitro, ZNF202
.-660G versus g.-660A was associated with a 60% reduc-
ion in transcriptional activity. In a cross-sectional study
f 5467 individuals from the Danish general population,
G-versus AA-homozygosity predicted an odds ratio for
evere atherosclerosis of 2.01. In 10,522 individuals from
he Danish general population, The Copenhagen City Heart
tudy, including 1526 incident IHD events during 28 years of
ollow-up, GG-versus AA-homozygosity predicted a hazard
atio for IHD of 1.21(1.02–1.35). Finally in two indepen-
ent case–control studies including, respectively, 943 and
549 cases with IHD and 8996 controls, equivalent odds
atios for IHD were 1.29 (1.02–1.62) and 1.60 (1.34–1.92).
n conclusion, homozygosity for a common functional
romoter variant in the transcriptional repressor ZNF202
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. Session V
Metabolic syndrome: chaired by Fredrik Karpe (Oxford,
K) and Folkert Kuipers (Groningen, The Netherlands).
The session on the metabolic syndrome was initiated by
ark McCarthy (Oxford, UK) who reviewed the recent rapid
rogress in identifying novel genes for type 2 diabetes and
besity. The discovery of the genetic background to mono-
enic forms of diabetes has been addressed with conventional
echniques through segregation analysis, whereas the com-
on genetic variants underlying complex diseases have been
lusive and often difficult to replicate. The problem has been
ery much described as an issue of power and recent devel-
pments of novel technological platforms together with large
nd aggregated patient cohorts (for example, the Wellcome
rust Case-Control Consortium) has made it possible to iden-
ify several novel targets, of which the obesity FTO gene
s a good example. Not unexpectedly, such common genes
how low odds ratio for disease when assessed properly. The
ext challenge is to search for less common genetic vari-
nts (allele frequencies of 1–5%), probably with higher odds
atio for disease; that gap is still to be filled for a more com-
lete understanding of the genetic background to obesity and
iabetes.
Børge Nordestgaard (Herlev, Denmark) described the
ower of non-fasting triglycerides as risk marker for myocar-
ial infarction, ischemic heart disease and death in the
openhagen City Heart study including more than 13,000
eople followed for 26 years. Non-fasting triglycerides
nclude remnant lipoproteins and the atherogenic properties
f such lipoproteins were offered as an explanation for the
trong positive relationship between triglycerides and heart
isease.
Hans Dieplinger (Innsbruck, Austria) described the iden-
ification of afamin, a vitamin E-binding glycoprotein,
s strongly related to the metabolic syndrome. This was
chieved using a comparative proteomic approach and then
earching for an association between afamin concentrations
nd parameters of the metabolic syndrome in the Bruneck
tudy (n = 825). A causal relationship of unknown nature was
uggested as mice with a transgenic overexpression of afamin
how signs of metabolic dysregulation compatible with the
etabolic syndrome.
Bert Groen (Amsterdam, The Netherlands) described
nvestigations of the use of iminosugars in the regulation of
eatures of the metabolic syndrome in mice. The iminosugar
MP-DNM upregulated CYP7A1 and drastically altered the
ile composition. The mechanism for this effect appeared to
e mediated through inhibition of FGF19, which otherwise
ownregulates CYP7A1.
Finally, Sandra Schreyer (Molndahl, Sweden) described
he efforts to investigate the role of mitochondrial glycerol-3-
hosphate acyl-transferase (mtGPAT) in hepatic triglyceride
ynthesis. Overexpression of mtGPAT in liver resulted in
epatic steatosis in chow fed mice. However, the mtG-
AT knockout mouse showed a surprisingly mild phenotype.
n
m
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hen these mice were fed a high fat diet there was no impact
n obesity or hepatic triglyceride content suggesting that
tGPAT does not play a critical role in regulating triglyceride
ynthesis in the liver.
Claudia Coomans (Leiden, The Netherlands) addressed
he role of the central nervous system in control of plasma
riglyceride metabolism, particularly whether an increase in
entral insulin availability would influence the tissue-specific
istribution of plasma free fatty acids (FFA) and triglyceride-
erived fatty acids. It was shown that continuous infusion of
mall amounts of insulin into the lateral ventricle of fasted
ice promotes the uptake of both FFA and triglyceride-bound
atty acids in adipose tissue, but not in liver, heart and muscle.
hus, insulin acts by both direct and indirect (i.e., via the
rain) means to stimulate energy storage in adipose tissue.
Peter J Voshol (Leiden, The Netherlands) demonstrated
hat over-expression of apoC-I aggravates hepatic inflamma-
ion, as deduced from increased NF-kB activation, in mice
ed a high fat diet. In addition, in spite of the fact that apoC-I
verexpression did not alter food intake, body weight gain
r energy expenditure of the mice, it did result in a marked
eripheral and hepatic insulin resistance, indicative for a
odulatory role of apoC-I in the development of several
omponents of the metabolic syndrome.
Leanne Hodson (Oxford, UK) presented results of a stable
sotope study in humans addressing the relative contributions
f dietary and splanchnic fatty acids to VLDL production by
he liver in control and insulin-resistant subjects, the latter
ith high plasma VLDL-triglyceride levels. She was able
o show that, at 6 h after a test meal, most of the difference
etween the groups was accounted for by a much larger con-
ribution of splanchnic fat in the insulin-resistant subjects: the
ontribution of dietary fatty acids and endogenous systemic
FA was similar between both groups.
Sabine Ru¨tti (Zu¨rich) studied the effects of HDL isolated
rom healthy human donors on human and mouse pancre-
tic  cell turnover and function. Using a variety of in vitro
echniques, she was able to show that HDL induces human
slet cell proliferation and protects human and mouse islet
ells from glucose- and Il-1-induced apoptosis. Induction
f FLIP mRNA expression by HDL was proposed as a poten-
ial mechanism. HDL did not affect -cell secretory function
s assessed by glucose-stimulated insulin secretion.
. Session VI
Varia: chaired by Athina Kalopissis (Paris, France) and
rnold von Eckardstein (Zurich, Switzerland).
Oral contributions at the varia session included, as has
ecome a tradition, a diversity of topics and molecules
nvolved in lipid metabolism and atherosclerosis.Tim Vanmierlo (Maastricht, The Netherlands) presented
ew data on Liver X Receptor (LXR) activation in a mouse
odel of Alzheimer’s Disease (AD mice). Because the activa-
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educed levels of secreted amyloid-, the cognitive functions
f 21 month-old AD mice were evaluated after long-term
reatment with the synthetic LXR agonist TO901317. The
patial and object memory of old AD mice was improved,
robably through alterations in brain cholesterol metabolism.
XR agonists may provide a future treatment for improve-
ent of clinical outcome of AD patients.
Oliver Bruns (Hamburg, Germany) received this year′s
oung Investigator Award for his presentation of “Non-
nvasive in vivo imaging of recombinant TRL labeled with
anocrystals”. To avoid radioactive lipid labels, the lipid
ore of triglyceride rich lipoproteins (TRL) was labeled
ith lipophilic superparamagnetic iron oxide nanocrystals.
icelles were formed and apoE and lipoprotein lipase were
ssociated to obtain recombinant TRL (rTRL), which had a
iameter of 250 nm. After injection into mice, the turnover
nd organ uptake of rTRL was followed by dynamic MRI
ith a time resolution of 3 s. rTRL were rapidly cleared from
he blood and taken up into liver (internalized in hepatocytes),
pleen and bone marrow. This new labeling technique allows
on-invasive imaging to study postprandial lipoprotein kinet-
cs.
Scavenger receptor class B type I (SR-BI) play a major
ole in selective uptake of HDL-C in rodents. Menno Vergeer
Amsterdam, The Netherlands) and colleagues sequenced
he SR-BI gene in 162 unrelated subjects with hyperal-
halipoproteinemia and described the identification of a
ubject heterozygous for a point mutation resulting in P297S.
uantitative trait locus (QTL) analyses with 123 members
f this subject’s family (carriers and unaffected) showed an
llelic effect of +0.39 ± 0.09 mmol/L on HDL cholesterol
evels. P297S carriers exhibited a 17% increase in apo AI lev-
ls, whereas fractional cholesterol efflux from their cultured
rimary macrophages was 20% lower. This study suggests
hat SR-BI may be important in controlling HDL metabolism
n humans.
The final session of this year’s ELC meeting was started by
he presentation of the young investigator poster award win-
er. Philip Gordts (Leuven, Belgium) investigated the role
f the distal intracellular NPXY-motif of the LDL receptor
elated protein LRP1. He and his colleagues used a knock-
n approach to inactivate the distal NPXY motif of LRP1
n mice. After crossing with LDL-receptor knockout mice
hese mice showed aggravated dyslipidemia and enhanced
therosclerotic lesion development. Possible reasons include
he more atherogenic lipoprotein profile and disturbed PDGF
ignalling.
Ernst Steyrer (Graz, Austria) investigated the effects of
hosphatidylethanolamine N-methyltransferase (PEMT) on
he formation and stability of lipid droplets. This enzyme
onverts phosphatidylethanolamine (PE), which has a conical
hape, into phosphatidylcholine (PC, cylindrical shape) and
s therefore assumed to play an important role in the fission
f lipid droplets from the ER. In line with its function, inhibi-
ion or absence of PEMT enhanced basal lipolysis in 3T3-L1
dipocytes and in tissue samples from PEMT-knockout mice,is 197 (2008) 471–479
espectively. Conversely, overexpression of PEMT decreased
ree fatty acid release from adipocytes. In summary, lipid
roplet stability seems to be affected by the ratio between
E and PC as constituents of the lipid droplet phospholipid
onolayer.
By using turnover studies in mice in conjunction with
icroscopic techniques Andreas Niemeier and colleagues
Hamburg, Germany) showed that bone is an important tis-
ue taking up chylomicron remnants from the circulation. On
he cellular level, sinusoidal endothelial cells, macrophages
nd notably osteoblasts were found to bind and internalize
hylomicron remnants. Enrichment of chylomicrons with
itamin K led to enhanced carboxylation of osteocalcin in
ivo. It is concluded that bone is a physiologically important
ite of chylomicron remnant uptake, possibly to ensure the
upply of bone with lipid soluble vitamins.
The two final presenters exploited the fruit fly Drosophila
s a powerful genetic model to study the evolutionary conser-
ation of important players in lipid metabolism and to identify
nd characterize novel key factors. By using reverse genet-
cs, transcriptomics and subcellular proteomics, Ronald P.
u¨hnlein (Go¨ttingen, Germany) studied fat storage regulation
nd identified the triglyceride lipase Brummer as a homolog
f adipose triglyceride lipase, the lipolytic G-protein cou-
led receptor AKHR and the PAT domain proteins Lsd-1
nd Lsd-2 as relatives of the cage protein perilipin. Alex P.
ould (London, UK) identified oenocytes as a cell type which
ccumulates lipids that are released from fat body during star-
ation. In addition, oenocytes were found to express more
han 20 genes which are involved in lipid metabolism. It is
oncluded that in insects oenocytes exert lipid processing
unctions that in mammals are accomplished by the liver.
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